Amarin Shares Have Downside To $3 On Patent Loss, Says Northland
September 03, 2020 at 09:20 AM EDT
An unfavorable Vascepa patent ruling from the Court of Appeals Federal Circuit can place the shares of Amarin in the $3 range, Northland analyst Carl Byrnes tells investors in a research note.
